Physician profile
Audrey Fenwick
NPI 1922585108
$29,398.51
in general payments reported to CMS, 2019-2025
27 companies · $6,202 in 2025
The $6,202 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,111 · 2023: $15K · 2024: $5,672 · 2025: $6,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $5,634 · Travel and Lodging: $4,581 · Food and Beverage: $4,089 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,810.00 |
| Consulting Fee | $5,633.50 |
| Travel and Lodging | $4,581.48 |
| Food and Beverage | $4,088.74 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25,455.06 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $1,197.12 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $541.41 | 2022-2025 | |
| Abbvie INC. | $381.48 | 2022-2025 | |
| Aspira Women'S Health INC | $264.75 | 2022-2023 | Ova1 |
| Biogen, INC. | $226.69 | 2024-2025 | Zurzuvae |
| Astellas Pharma Global Development | $214.82 | 2024-2025 | Veozah |
| Radius Health, INC. | $141.10 | 2025 | Tymlos |
| Exeltis, USA INC. | $138.38 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $109.12 | 2022-2025 | Acessa Provu System, Novasure, Aptima |
| Sumitomo Pharma America, INC. | $102.79 | 2023-2025 | Myfembree, Gemtesa |
| Seqirus USA INC | $97.04 | 2024 | Fluad, Flucelvax |
| Myovant Sciences INC. | $79.73 | 2022 | |
| Organon LLC | $77.43 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $64.34 | 2023-2024 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $44.24 | 2022 | |
| Millicent US INC | $44.08 | 2025 | Femlyv, Intrarosa |
| Novo Nordisk INC | $40.11 | 2023 | Wegovy |
| Therapeuticsmd, INC. | $35.99 | 2022 | |
| Lilly USA, LLC | $29.58 | 2024 | Zepbound |
| Amgen INC. | $19.12 | 2025 | Evenity |
| Pharmacosmos Therapeutics INC. | $17.98 | 2024 | Monoferric |
| Evofem Biosciences, INC. | $16.69 | 2022 | |
| Merck Sharp & Dohme LLC | $16.01 | 2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $15.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.24 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Fenwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.